PL447248A1 - Granulat zawierający związek maślanu sodu, jego formy i zastosowanie - Google Patents

Granulat zawierający związek maślanu sodu, jego formy i zastosowanie

Info

Publication number
PL447248A1
PL447248A1 PL447248A PL44724823A PL447248A1 PL 447248 A1 PL447248 A1 PL 447248A1 PL 447248 A PL447248 A PL 447248A PL 44724823 A PL44724823 A PL 44724823A PL 447248 A1 PL447248 A1 PL 447248A1
Authority
PL
Poland
Prior art keywords
granulate
weight
subject
amount
application
Prior art date
Application number
PL447248A
Other languages
English (en)
Inventor
Adam Kiciak
Original Assignee
Probiome Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probiome Spółka Z Ograniczoną Odpowiedzialnością filed Critical Probiome Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL447248A priority Critical patent/PL447248A1/pl
Priority to PCT/PL2024/050102 priority patent/WO2025136132A1/en
Publication of PL447248A1 publication Critical patent/PL447248A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Przedmiotem zgłoszenia jest granulat zawierający związek maślanu w matrycy acyloglicerolowej charakteryzujący się tym, że zawiera związek maślanu, korzystnie maślan sodu albo tributyrynę, w ilości od 40% do 86% wagowych całkowitej masy granulatu acyloglicerole w ilości od 14% do 58% wagowych całkowitej masy granulatu liczonej, przy czym stanowią one mieszaninę diacylogliceroli i monoacylogilceroli farmaceutyczne akceptowalne substancje pomocnicze w ilości od 0 do 10% wagowych całkowitej masy granulatu. Przedmiotem zgłoszenia jest też jednostkowa doustna postać dawkowania charakteryzująca się tym, że jest wypełniona lub wytworzona na bazie powyższego granulatu. Zgłoszenie obejmuje też zastosowanie przedmiotowego granulatu do leczenia zespołu rozrostu bakteryjnego jelita cienkiego.
PL447248A 2023-12-22 2023-12-22 Granulat zawierający związek maślanu sodu, jego formy i zastosowanie PL447248A1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL447248A PL447248A1 (pl) 2023-12-22 2023-12-22 Granulat zawierający związek maślanu sodu, jego formy i zastosowanie
PCT/PL2024/050102 WO2025136132A1 (en) 2023-12-22 2024-12-18 Granulate comprising a butyrate compound, its forms and uses

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL447248A PL447248A1 (pl) 2023-12-22 2023-12-22 Granulat zawierający związek maślanu sodu, jego formy i zastosowanie

Publications (1)

Publication Number Publication Date
PL447248A1 true PL447248A1 (pl) 2025-06-23

Family

ID=96092933

Family Applications (1)

Application Number Title Priority Date Filing Date
PL447248A PL447248A1 (pl) 2023-12-22 2023-12-22 Granulat zawierający związek maślanu sodu, jego formy i zastosowanie

Country Status (2)

Country Link
PL (1) PL447248A1 (pl)
WO (1) WO2025136132A1 (pl)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013025112A1 (en) * 2011-08-12 2013-02-21 Mifarmex Sp. Z.O.O. Combination of sodium butyrate and organic acids for preventing and reducing diarrhoeas
PL233287B1 (pl) * 2016-08-11 2019-09-30 Luczynska Katarzyna Chemprof Doradztwo Chemiczne Spolka Cywilna Granulat zawierający związek maślanu, sposób jego otrzymywania oraz jego zastosowanie
CN116115646A (zh) * 2021-12-31 2023-05-16 龙岩新奥生物科技有限公司 一种抑菌组合物及其制备方法和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017279782A1 (en) * 2017-12-22 2019-07-11 BIOLEK Sp. z.o.o. Compositions for gastrointestinal disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013025112A1 (en) * 2011-08-12 2013-02-21 Mifarmex Sp. Z.O.O. Combination of sodium butyrate and organic acids for preventing and reducing diarrhoeas
PL233287B1 (pl) * 2016-08-11 2019-09-30 Luczynska Katarzyna Chemprof Doradztwo Chemiczne Spolka Cywilna Granulat zawierający związek maślanu, sposób jego otrzymywania oraz jego zastosowanie
CN116115646A (zh) * 2021-12-31 2023-05-16 龙岩新奥生物科技有限公司 一种抑菌组合物及其制备方法和应用

Also Published As

Publication number Publication date
WO2025136132A1 (en) 2025-06-26

Similar Documents

Publication Publication Date Title
AR020015A1 (es) Composiciones de celecoxib
BRPI0508833A (pt) formulações galênicas de compostos orgánicos
GT198304062A (es) Derivado epimerico de azahomoeritromicina a e intermedios del mismo
MA31706B1 (fr) Formulations galéniques de composés organiques
ITBO20110012A1 (it) Composizioni farmaceutiche comprendenti rifaximina e loro uso.
RU2012142811A (ru) Фармацевтические композиции и пероральные дозированные формы пролекарства леводопы и способы применения
MX2024013914A (es) Moduladores del inflamasoma nlrp3 y productos y metodos relacionados
AP1849A (en) Dosage regimen and pharmaceutical composition for emergency contraception
TW202031263A (zh) 抑制軟性隱形眼鏡變質之眼科用組成物
PH12022551798A1 (en) Use of benzoate compound in treatment of sars-cov-2 infection
DK1201246T3 (da) Anvendelse af trombopoietin som et medikament til behandling og forebyggelse af trombocytopeni
PL447248A1 (pl) Granulat zawierający związek maślanu sodu, jego formy i zastosowanie
ES2149733T1 (es) Composicion farmaceutica oral con liberacion modificada que contiene 5-asa y metodo para el tratamiento de enfermedades intestinales.
US20230094778A1 (en) Treatment of moderate and severe gastroparesis
MX2024010596A (es) Composiciones que comprenden 5-metoxi-2-aminoindano (meai) y n-aciletanolaminas y usos de las mismas
ES2180546T3 (es) Composicion basica administrable percutaneamente y composicion de farmaco preparada a partir de ella.
CA2655485A1 (en) Penem prodrugs
US11872216B2 (en) Pharmaceutical formulation comprising cineole and amoxicillin
GR3019274T3 (en) Substituted 3-piperazinylalkyl-2,3-dihydro-4H-1,3-benzoxazine-4-ones, their preparation and their therapeutical use
MX2025007032A (es) Composicion farmaceutica tipo colirio que contiene enavogliflozina
IL35341A (en) Antibiotic synergistic compositions containing primycin and another antibiotic and their preparation
IL276576B1 (en) Therapeutic factors for the treatment of restless legs syndrome
EP0617962A4 (en) OBESITY INHIBITOR.
PH12023550177A1 (en) Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound.
MX2023009620A (es) Metodos terapeuticos.